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BACKGROUND: Previously, we have shown that low IL-12p40 mRNA expression by cervical cancer cells is associated with a poor
survival of cervical cancer patients. As IL-12p40 is both a subcomponent of interleukin (IL)-12 and IL-23, the aim of this study was to
elucidate the role of IL-12p40 in cervical cancer.
METHODS: We have measured the expression of IL-23p19 mRNA, IL-12p35 mRNA and IL-12p40 mRNA using mRNA in situ
hybridisation. The IL-1 and IL-6 were measured by immunohistochemistry.
RESULTS: As IL-23 is a component of the IL-17/IL-23 pathway, a pathway induced by IL-1 and IL-6 in humans, we have studied IL-1 and
IL-6 expression. Only a high number of stromal IL-6-positive cells was shown to associate with poor disease-specific survival. The
worst disease-specific survival was associated with a subgroup of patients that displayed a high number of IL-6-positive cells and low
IL-12p40 expression (Po0.001). Both a high number of IL-6-positive cells and a high number of IL-6-positive cells, plus low IL-12p40
expression were shown to be clinicopathological parameters independent of lymph node metastasis, parametrial involvement and
Sedlis score (P¼ 0.009 and P¼ 0.007, respectively).
CONCLUSION: Our results with IL-6 and IL-12p40 are in accordance with the hypothesis that the IL-17/IL-23 pathway has a suppressive
role in cervical cancer.
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Cervical cancer is a leading cause of morbidity and mortality
among women worldwide, especially in the developing countries
(Munoz, 2000; Rock et al, 2000). Infection with oncogenic types of
human papillomavirus (HPV) is an important factor in the
development of cervical cancer (Schwartz et al, 2001; Waggoner,
2003). The persistent HPV infection induces an inflammatory
response. Inflammation is an important component in the
majority of tumour types. The outcome of this inflammatory
response surrounding the cancer cells is dependent on the
composition of the inflammatory infiltrate and locally produced
signalling molecules (Coussens and Werb, 2002). Although
inflammatory cells within the neoplastic lesion are capable of
generating an anti-tumour response, this does not efficiently occur
(Elgert et al, 1998; Manna and Mohanakumar, 2002).
Inflammatory cells are attracted to the tumour site by locally
produced cytokines and chemokines (Balkwill, 2003; Vicari et al,
2004). Cervical cancer cells are known to produce an extensive
range of cytokines and chemokines, such as CCL2, GM-CSF, TNFa
and interleukin (IL)-12 (Clerici et al, 1997; Hazelbag et al, 2001;
Zijlmans et al, 2006). In addition to attracting inflammatory cells,
these cytokines and chemokines influence the activation status and
function of infiltrating antigen-presenting cells and stromal cells,
thus influencing the course of the disease (Kusmartsev and
Gabrilovich, 2002; Balkwill, 2003).
In a previous study, we have shown that high expression levels or
undetectable levels of IL-12p40 mRNA in cervical carcinoma are
associated with an improved overall survival compared with low
amounts of IL-12p40 that were associated with poor survival
(Zijlmans et al, 2007). As IL-12 is known to stimulate effector cell
populations, such as cytotoxic T cells and natural killer cells (Strobl,
2003; Trinchieri, 2003), our results suggest a dual role for IL-12p40.
The IL-12 cytokine family includes IL-12, IL-23, IL-27 and IL-35
(Xu et al, 2010). From this family, IL-12 and IL-23 share the
IL-12p40 subchain. Interleukin-12 is composed of IL-12p40 and
IL-12p35, whereas IL-23 is composed of IL-12p40 and IL-23p19.
Interleukin-23 has, amongst others, an important role in the IL-17/
IL-23 pathway, resulting in the maintenance and expansion of
Th17 cells (Korn et al, 2009). In addition to IL-23, IL-1 and IL-6 are
thought to have an important role in the induction of Th17 cells in
humans (Acosta-Rodriguez et al, 2007). The effect of IL-23 on
cancer progression or cancer eradication is still not clear
(Langowski et al, 2006; Shan et al, 2006).
To further delineate the role of IL-12p40 in cervical carcinoma,
we have quantified the mRNA expression levels of IL-23p19,
and compared its expression level with IL-12p35 and IL-12p40 to
investigate the relative importance of IL-12 and IL-23 in the
tumour microenvironment. In addition, we have investigated
the role of IL-1 and IL-6 in the tumour microenvironment
by determining both the number of IL-1-positive cells
and the number of IL-6-positive cells. Finally, we have assessed
the association between IL-23p19, IL-12p35, IL-12p40,
high number of IL-6-positive cells and clinicopathological
parameters.
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MATERIAL AND METHODS
Patient material
Between 1985 and 1995, 254 untreated patients suffering from
primary cervical carcinoma with stage IB and IIA underwent a
radical hysterectomy type III with lymphadenectomy. From the
tissue obtained, based on the availability of the material, 90 tissue
samples were accessible for research. Tissues were routinely
embedded in paraffin after 10% formalin fixation. The tissue
samples of each patient were examined by a pathologist for the
presence of tumour. Tumour percentage varied between 20% and
90%, with median 60%. The characteristics of the patients are
depicted in Table 1. Forty-seven patients received post-operative
radiotherapy because of either tumour-positive lymph nodes or
the presence of positive risk factors described by the Sedlis criteria
(Sedlis et al, 1999; a combination of two of the following
unfavourable prognostic parameters: depth of infiltration
X15mm (deep stromal invasion; middle or deep third), tumour
size X40mm and presence of vasoinvasion). Human tissue
samples were used according to the guidelines of the Ethical
Committee of the Leiden University Medical Centre.
Preparation of IL-23p19, IL-12p35 and IL-12p40 probes
RNA was isolated from frozen human spleen using TRIzol
(Invitrogen, Breda, The Netherlands) and first-strand cDNA was
synthesised with oligoDT primers and Reverse Transcriptase AMV
(both from Roche Diagnostics GmbH, Mannheim, Germany), both
according to manufacturer’s instructions. Oligonucleotide primers
for IL-23-p19, IL-12p35 and IL-12p40 were chosen on the basis of
known sequences (see Table 2), and cDNA encoding for the
different cytokines was amplified. A pGEM-3Zf(þ ) Vector
(Promega, Madison, WI, USA) was linearised with SmaI and the
PCR products were cloned into the vector. After transferring the
vector to E. coli strain Top 10 (Invitrogen Corp., San Diego, CA,
USA), the plasmids were isolated by using the QIAfilter Maxi KITS
protocol (QIAGEN GmbH, Hilden, Germany). The sequence of the
PCR product was confirmed by DNA sequencing. Plasmids were
linearised with BamH1 and EcoR1 (both from Boehringer,
Mannheim, Germany) in case of IL-12p40, with BamH1 and SacI
in case of IL-12p35 and with SacII, SalI and SpeI (Boehringer) in
case of IL-23p19, using One-Phor-All Buffer Plus (Amersham
Biosciences, Roosendaal, The Netherlands). Both strands were
translated in a digoxigenin (DIG)-labelled RNA probe according to
manufacturer’s instructions (Roche Diagnostics GmbH). The
concentration of the DIG-labelled sense and antisense RNA probes
were determined on a 1% agarose gel stained with ethidium
bromide (Sigma, St Louis, MO, USA). Probes were stored at
 20 1C until further use.
RNA in situ hybridisation
The RNA in situ hybridisation (RISH) was performed as previously
described (de Boer et al, 1998; de Boer et al, 2000). In short, 3 mm
thick paraffin sections were pre-treated and hybridised with
100 ngml 1 DIG-labelled RNA probe diluted in hybridisation
mixture containing NaCl and saline-sodium citrate (SSC; Table 2).
Hybridisation was allowed for 16 h at either 55 1C (IL-23p19) or
42 1C (IL-12p35 and IL-12p40) in a humidified chamber. Slides
were washed 30min in 2 SSC, followed by 45min in 0.1 SSC
with 20mM b-mercaptoethanol (Merck, Darmstadt, Germany),
both used at hybridisation temperature (see Table 2). Subse-
quently, the slides were incubated for 30min with 2Uml 1
ribonuclease (RNase) T1 (Roche Diagnostics GmbH) in 2 SSC,
1mM EDTA at 37 1C. RNA hybrids were detected using,
subsequently, mouse anti-DIG (1 : 2000, Sigma-Aldrich Chemie
GmbH, Steinham, Germany), rabbit anti-mouse Ig (1 : 50, DAKO,
Glostrup, Denmark) and mouse alkaline phosphatase anti-alkaline
phosphatase (APAAP, DAKO; Hazelbag et al, 2001).
Immunohistochemistry
Serial sections, 3-mm thick, of formalin-fixed and paraffin-
embedded tissue were mounted on aminopropylethoxysilane-
coated slides. Sections were deparaffinised, rehydrated and treated
with 0.3% H2O2 in methanol for 20min to block endogenous
peroxidase activity.
Antigen retrieval was performed (0.01 M citrate, pH 6.0) and
sections were rinsed in phosphate-buffered saline (PBS). Subse-
quently, sections were stained overnight using either a 1 : 100
dilution of an affinity-purified polyclonal goat anti-human IL-1b
antibody (AF-201-NA; R&D Systems, Minneapolis, MN, USA) or a
1 : 300 dilution of anti-human polyclonal rabbit anti-IL-6 antibody
(Abcam, Cambridge, UK). For anti-IL-1, the slides were incubated
with a goat HRP-polymer kit (Biocare Medical, Concord, CA, USA)
according to the manufacturer’s instructions. For anti-IL-6, the
slides were incubated with a biotinylated swine anti-rabbit
antibody (1 : 200; DAKO) and subsequently incubated with a
biotinylated horseradish peroxidase – streptavidin complex
(1 : 100, DAKO), respectively. Immune complexes were visualised
with diaminobenzidine as previously described (de Boer et al,
2000).
(Semi-)quantitative evaluation of RISH and
immunohistochemistry
RISH was scored as previously described (Ruiter et al, 1998).
Intensity was scored as none (0), mild (1), moderate (2) or intense
(3) at low magnification ( 100). Furthermore, the percentage of
positive tumour cells was determined and divided in 6 groups:
0% (0, absent), 1–5% (1, sporadic), 6–25% (2, local), 26–50%
(3, occasional), 51–75% (4, majority) and 76–100% (5, large majority).
Table 1 Summary of clinicopathological features of patients and tumours
Patient and tumour characteristics Outcome Na
Age 45 (mean) 90
29–76 (range)
FIGOb stage IB 68
IIA 21
Lymph node metastasis No 66
Yes 22
Tumour sizeb o 40mm 37
X 40mm 26
Depth of infiltrationb o 15mm 58
X 15mm 26
Vascular space involvementb No 39
Yes 47
Sedlis criteriac Positive 28
Negative 52
Parametrial invasionb No 74
Yes 14
HPV statusd 16, 18 66
Others 15
Histology Squamous 58
Adenosquamous 18
Adeno 7
Others 6
Abbreviations: FIGO¼ International Federation of Gynecology and Obstetrics; HPV¼
human papillomavirus. aN is the number of patients/cervical carcinomas. bThe number of
reported cases is affected by incidental missing cases. cSedlis criteria (Sedlis et al, 1999):
a combination of two of the following unfavourable prognostic parameters: depth of
infiltrationX15mm (deep stromal invasion; middle or deep third), tumour size X40mm
and presence of vasoinvasion. dOnly data for cervical carcinoma samples with a determined
HPV type were included. Other subtypes included HPV31 (n¼ 2), HPV33 (n¼ 6),
HPV35 (n¼ 1), HPV45 (n¼ 3), HPV58 (n¼ 1), HPV59 (n¼ 2) and HPV68 (n¼ 1).
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The sum of both the percentage and the staining intensity of the
positive cells resulted in an overall score (0 or 2 to 8). The scores
were combined into three groups: category 0 (score 0, no
expression), category 1 (scores 2, 3, 4 and 5, low expression) and
category 2 (scores 6, 7 and 8, high expression). mRNA expression
was scored by two independent researchers without knowing the
identity and clinical outcome of the patients. The IL-1-positive
cells and IL-6-positive cells were quantified in the tumour by
counting the number of stained cells per six, randomly selected,
high-power field of view (HPF,  400).
Statistical analysis
Data from immunohistochemistry as well as RISH are given as the
mean±s.d. Statistical analysis was done using SPSS 17.0 (SPSS
Inc., Chicago, IL, USA). Data were processed by using the w2-test.
Kaplan–Meier survival curves were generated to assess differences
in disease-free period (defined as the observation time in months
from surgery to relapse of the disease (disease-free survival)) or
cumulative disease-specific survival (defined as time in months
from surgery to death due to cervical cancer). A Cox regression
was used for multivariate survival analysis. A value of Po0.05 was
considered statistically significant.
RESULTS
Patients
Of the group of 90 patients, 68 patients were diagnosed as FIGO
stage IB and 21 patients as FIGO stage IIA, and all underwent
radical hysterectomy combined with pelvic lymph adenectomy
(Table 1). Forty-seven patients received post-operative radio-
therapy because of either tumour-positive lymph nodes or meeting
the terms of the Sedlis criteria (Sedlis et al, 1999; a combination of
two of the following unfavourable prognostic parameters: depth of
infiltrationX15mm, tumour sizeX40mm and presence of vasoin-
vasion). Twenty-five patients suffered recurrent disease. At the end
of the study, 70 patients were alive, 7 suffered from a recurrence
and 18 patients had died of disease.
Expression of IL-23p19, IL-12p35 and IL-12p40 in cervical
cancer
As IL-12p40 is both a subunit of IL-12 and IL-23, we have
determined the expression of IL-23p19. Both IL-23p19 and
IL-12p40 were expressed by cervical tumour cells (Figure 1A
and C). The expression of IL-12p40 was stronger than the
expression of IL-23p19. IL-23p19 was expressed in 63% of the
samples (n¼ 54), IL-12p40 was expressed in 54% of the samples
(n¼ 90) and IL-12p35 was expressed in 84% of the samples
(n¼ 90; Table 3). All samples that expressed either IL-23p19 or
IL-12p40 also expressed IL-12p35 mRNA. In contrast, 13 out of 44
samples that expressed IL-12p40 did not express IL-23p19.
A positive correlation between IL-23p19 and IL-12p40 was found
(n¼ 54, r2¼ 0.117, P¼ 0.011; data not shown). No statistically
significant correlation between IL-23p19 and IL-12p35 was found
(n¼ 54, r2¼ 0.061, P¼ 0.072; data not shown).
Association between IL-23p19, IL-12p35 and IL-12p40,
and disease-specific survival in cervical cancer
To investigate the relationship between the expression of IL-
23p19, IL-12p35 and IL-12p40, and disease-specific survival,
Kaplan–Meier plots were created. A log-rank test was used to
determine statistical differences in disease-specific survival. As
the absence of IL-12p40 will result in neither IL-12 nor IL-23, we
first confirmed that expression of IL-12p40 was associated with
poor disease-specific survival (Figure 2A; n¼ 48, log-rank test
5.753, P¼ 0.017) in this cohort. The expression of IL-12p35
(Figure 2B; n¼ 74, log-rank test 0.2019, P¼ 0.653) and the
expression of IL-23p19 (Figure 2C; n¼ 33, log-rank test 1.930,
P¼ 0.165) were both not significantly associated with disease-
specific survival. The expression of IL-23p19, IL-12p35 or IL-12p40
showed no significant difference in disease-free survival (data not
shown).
Presence of IL-6-positive cells and association with
disease-specific survival in cervical cancer
The presence of IL-23p19 suggests that IL-23 may sustain a Th17-
positive cell population in cervical cancer. As differentiation
towards the IL-17/IL-23 pathway is thought to occur in the
presence of IL-1 and IL-6 in humans (Acosta-Rodriguez et al,
2007), we have determined the presence of IL-1 and IL-6-positive
cells, using immunohistochemistry. Interleukin-1 was predomi-
nantly expressed by cells in the stromal compartment. Occasion-
ally, tumour cells also showed weak IL-1 expression. No
statistically significant association between low or high number
of IL-1-expressing cells and disease-specific survival was observed
(Figure 3A). Interleukin-6 was expressed by both cells in the
epithelial (tumour cell) compartment and cells in the stromal
compartment (Figure 1E). No significant association was observed
between low or high IL-6 expression of cells in the epithelial
compartment and disease-specific survival (Figure 1F). Subse-
quently, we quantified the number of IL-6-positive cells in the
stroma. The presence of a high number of IL-6 stromal positive
cells (median 17 IL-6-positive cells/HPF) significantly associated
with disease-specific survival (Figure 3B; n¼ 83, log-rank test
12.57, Po0.001). No statistical significant difference was observed
for disease-free survival (data not shown). We also determined
whether disease-specific survival was associated with the presence
of both a high number of IL-6-positive stromal cells and low IL-
12p40. In this latter case, an even stronger decrease in disease-
specific survival was observed (Figure 3C; n¼ 47, log-rank test
20.38, Po0.001).
Table 2 RNA probes used and RNA-in situ hybridisation conditions
Target Primer Sequence (50–30) Product (bp) Accession number Position Hybr. temp. (1C)
IL-23p19 Forward AGAGCCAGCCAGATTTGAGA 487 NM_016584.2 134–620 55
Reverse GCAGATTCCAAGCCTCAGTC
IL-12p35 Forward TGCTCCAGAAGGCCAGACAAAC 465 XM_003121 320–784 42
Reverse CCCGAATTCTGAAAGCATGAAG
IL-12p40 Forward GGACCAGAGCAGTGAGGTCTT 373 XM_004011 189–561 42
Reverse CTCCTTGTTGTCCCCTCTGA
Abbreviation: Hybr. temp.¼ hybridisation temperature.
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Association between low IL-12p40 expression, high
number of IL-6-positive stromal cells and
clinicopathological parameters
To determine the relevance of our findings, we associated our
immunological findings with clinicopathological parameters. First,
a univariate Cox analysis was performed, using the clinical
parameters, Sedlis criteria (two out of three of the following
criteria positive: tumour sizeX40mm, vasoinvasion and deep
stromal invasion), lymph node metastasis and parametrial
involvement and the immunological parameters, low IL-12p40
expression, high number of IL-6-positive cells and high number of
IL-6-positive cells, plus low IL-12p40 expression. In the univariate
Cox analyses, all the included parameters showed a significantly
increased hazard ratio (HR; Table 4). Subsequently, a multivariate
Cox analysis with the three clinicopathological parameters and
each of the significantly immunological parameters was per-
formed. In this case, two of the three immunological parameters,
high number of IL-6-positive stromal cells (P¼ 0.009; HR, 7.447)
and high number of IL-6-positive stromal cells and low IL-12p40
expression (P¼ 0.007; HR, 20.123) were shown to be independent
predictors of poor disease-specific survival.
DISCUSSION
In a previous study, we found an association between low
expression of IL-12p40 and poor disease-specific survival, whereas
high expression of IL-12p40 or lack of expression of IL-12p40 were
associated with a favourable disease-specific survival (Zijlmans
et al, 2007). As IL-12p40 combines with both IL-12p35 and IL-
23p19, to form IL-12 and IL-23, respectively, in the present study,
we have further investigated the role of IL-12p40 in cervical cancer.
Both IL-23p19 and IL-12p35 were expressed in the majority of
the samples. Out of the 44 samples that expressed IL-12p40, 13
samples did not express IL-23p19. As IL-12p35 expression seems to
be ubiquitous in cervical cancer (Zijlmans et al, 2007), the level of
IL-12p40 or IL-23p19 expression most probably determines
whether IL-12, IL-23 or both are expressed. In our study, we
observed a trend (P¼ 0.061; n¼ 54) between IL-23p19 or IL-12-p35
expression, whereas in the study of Wolf et al (2010) in ovarian
cancer (n¼ 112) a significant correlation between the expression
of IL-23p19 and IL-12p35 was found. The discrepancy between our
results and the results of Wolf et al (2010) may be due to the
smaller size of our study group. Very few studies have investigated
the association between local expression of IL-12 or IL-23, and
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Figure 1 The expression of IL-23p19, IL-12p40 and IL-6. The expression of IL-23p19 and IL-12p40 were determined using RISH, and the expression of
IL-6 was determined using immunohistochemistry as described in the Materials and Methods ( 250 magnification). (A) Cervical tumour, IL-23p19 RISH.
Tumour cells stain positive (moderate) for IL-23p19; (B) negative (sense) control of IL-23p19 RISH; (C) cervical tumour, IL-12p40 RISH. Tumour cells stain
positive (strong) for IL-12p40; (D) negative (sense) control of IL-12p40 RISH. (E) IL-6 staining of cervical cancer tissue. Both cells in the epithelial
compartment (EC) as well as cells in the stroma express IL-6. Arrow indicates positive stromal cells. Detail ( 400 magnification) of IL-6-positive cells in the
stroma; and (F) association between cells in the epithelial compartment wit low (IL-6 EC low) and high IL-6 (IL-6 EC high) expression and disease-specific
survival. Bars correspond to 50mm in A–E and to 10mm in the inset of E. No significant association between low or high IL-6 expression of the epithelial
cells with disease-specific survival was observed.
IL-12p40 in cervical carcinoma
HJMAA Zijlmans et al
1959
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(12), 1956 – 1962
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
prognosis. Using immmunohistochemistry, IL-12 has been asso-
ciated with improved survival in patients with (advanced) gastric
carcinoma (Ye et al, 2007; Nagashima et al, 2008). In the study of
Wolf et al (2010), using RT-PCR, both IL-12p35 and IL-23-p19 were
associated with a superior outcome. In a multivariate analysis,
IL-12p35 was found to be an independent factor for overall survival
of ovarian carcinoma. As stated previously, we have observed a
statistically significant association between low expression of IL-
12p40 and poor disease-specific survival in cervical carcinoma
(Zijlmans et al, 2007). In the present study and our previous study
(Zijlmans et al, 2007), we did not find a significant association
between either IL-23p19 or IL-12p35 expression and disease-
specific survival. As IL-23p19 and IL-12p35 are both expressed, it is
important to determine which cytokine, IL-23 or IL-12, has a
dominant effect on the tumour microenvironment.
The molecular interaction between IL-23p19 and IL-12p40 has
been studied by Beyer et al (2008). These authors reported that the
interface region of IL-23p19 and IL-12p35 on IL-12p40 overlap.
Because of different interresidue interactions of IL-12p35 and IL-
23p19 with IL-12p40, these molecules interact with a different
affinity with IL-12p40. Therefore, the availability of IL-12p40 in
combination with the affinity for IL-12p35 and IL-23-p19 may
result in skewing of the IL-12/IL-23 response. This is supported by
experiments performed by Zwiers et al (2011). These authors
showed that in an experimental animal model, polymorphic
variants of IL-12p40 can skew IL-12/IL-23 synthesis (Zwiers
et al, 2011). Thus, both differences in protein interactions between
IL-23p19 and IL-12p35 on the one hand and IL-12p40 on the other
hand, and genetic polymorphisms in the protein chains, such as
IL-12p40, contribute to the amounts of IL-12 and IL-23 formed.
Our results support a previously suggested immunosuppressive
role for IL-23 (Langowski et al, 2006). This is further supported by
a study in ovarian carcinoma where genetic differences in the IL-23
receptor have been reported to influence prognosis (Zhang et al,
2010).
In contrast, it has also been shown that overexpression of IL-23
reduces tumour growth and metastasis formation, and that IL-23 is
able to elicit a strong cytotoxic T-cell memory response (Lo et al,
2003; Shan et al, 2006), underscoring our view that the level of
expression of the different cytokines and chemokines has an
import role in the final outcome.
Our data suggest that in the presence of a limited amount of
IL-12p40 the biological effect of IL-23 dominates, whereas in the
presence of a high amount of IL-12p40 the biological effect of IL-12
prevails. As IL-12 polarises the immune response towards an
antiviral response, (Trinchieri, 1994) the favourable cumulative
overall survival of patients with a high IL-12-positive cell density
(Ye et al, 2007; Nagashima et al, 2008) and high expression level of
IL-12p35 (Wolf et al, 2010) and IL-12p40 (Zijlmans et al, 2007) can
be explained by the capacity of this cytokine to increase the lytic
activity and the production of interferon-g of natural killer cells
and cytotoxic T lymphocytes (Trinchieri, 1994). Interestingly, we
previously observed an association between high expression of IL-
12p40 and high expression of TGF-b (P¼ 0.024; Zijlmans et al,
2007), suggesting that the tumour cells are selected to counter act
the effect of IL-12 or skew the response to the IL-17/IL-23 pathway.
In humans, in addition to IL-1, IL-6 and TGF-b have been
implicated to have a role in the IL-17/IL-23 pathway (Veldhoen
et al, 2006; Acosta-Rodriguez et al, 2007). Previously, we have
shown that it is likely that activated TGF-b is present in the tumour
microenvironment, as PAI-1, a target gene of TGF-b, is expressed
and expression of PAI-1 is associated with survival (Hazelbag et al,
2004). Furthermore, both the integrin avb6 and active matrix
metalloproteinase-2, known to activate TGF-b, are associated with
poor disease-specific survival (Sier et al, 2006; Hazelbag et al,
Table 3 Correlation between IL-23p19, IL-12p35 and IL-12p40
expression in cervical carcinoma.
IL-12p35
Expression Total
Cytokine level Absent Low High n (%)a
IL-12p40 Absent 14 21 6 41 (46)
Low 0 14 14 28 (31)
High 0 3 18 21 (23)
Total n (%)a 14 (16) 38 (42) 38 (42) 90 (100)
P-value o0.001
IL-23p19
IL-12p40 Absent 7 1 2 10 (19)
Low 8 5 11 24 (44)
High 5 4 11 20 (37)
Total n (%)a 20 (37) 10 (19) 24 (44) 54 (100)
P-value 0.188
IL-23p19
IL-12p35 Absent 1 0 0 1 (2)
Low 8 5 8 21 (39)
High 11 5 16 32 (59)
Total n (%)a 20 (37) 10 (19) 24 (44) 54 (100)
P-value 0.619
an¼ number of tumours. The scores were combined into three groups: absent
expression, low expression and high expression as described in Materials and
Methods. Statistically significant P–value is given in bold.
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Figure 2 Association between IL-12p40 (A), IL-12p35 (B) and IL-23p19 (C) expression and disease-specific survival in cervical carcinoma. IL-23p19,
IL-12p35 and IL-12p40 were determined by RISH as described in the Materials and Methods.
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2007). Even though the role of TGF-b in inducing Th17 in humans
has been questioned, TGF-b may suppress Th1 and Th2
development, thus favoring Th17 development (Santarlasci et al,
2009; Das et al, 2009).
In our study, low or high numbers of IL-1-positive cells were not
associated with disease-specific survival. The presence of a high
number of IL-6-expressing stromal cells was significantly asso-
ciated with poor disease-specific survival (Po0.001). Previously,
IL-6 has been implicated as an autocrine or paracrine growth
factor for cervical cancer (Tartour et al, 1994; Castrilli et al, 1997).
Interleukin-6 has been shown to induce VEGF transcription via the
STAT3 signalling pathway, thus promoting an angiogenic switch
(Wei et al, 2003). Indeed, blockade of the IL-6 receptor on cervical
cancer cell lines was shown to interfere with cell survival signals
and blocked the expression of VEGF (Su et al, 2005).
As HPV vaccines will become available for the treatment of
metastasised cervical carcinoma, the local cytokine/chemokine
profile may be important to discriminate patients with a beneficial
immune response from non-responding patients.
In conclusion, IL-12p40 has at least a dual role in cervical
carcinoma by associating with both IL-23p19 and IL-12p35. We
have shown that low IL-12p40 expression was significantly
associated with poor disease-specific survival (P¼ 0.017). Also, a
high number of stromal IL-6-producing cells was shown to
associate with poor disease-specific survival (Po0.001). The worst
disease-specific survival was observed in a subgroup of patients
that displayed a high number of stromal IL-6-expressing cells and
low IL-12p40 expression (Po0.001). Furthermore, both a high
number of stromal IL-6-expressing cells and a high number of
stromal IL-6, plus IL-12p40 expression, were shown to be
independent clinicopathological parameters compared with lymph
node metastasis, parametrial involvement and Sedlis score
(P¼ 0.009 and P¼ 0.022, respectively). Our results with IL-6 and
IL-12p40 are in accordance with the hypothesis that the IL-17/IL-23
pathway has a suppressive role in cervical cancer.
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